AstraZeneca’s Brilique Triumphs As First Drug Through Germany’s New Pricing Process
This article was originally published in The Pink Sheet Daily
Following negotiations, AstraZeneca’s clot buster Brilique has been awarded a price that has pleased both the manufacturer and health insurers – but industry as a whole remains skeptical of the system.
You may also be interested in...
AstraZeneca says that shortages of influenza vaccines in Germany are a direct result of the tendering process there, which has blocked the firm’s Fluenz nasal spray product from being prescribed in several federal states.
Plavix was a tough competitor before it went generic; now that cheap versions of the clot-buster are available, the market will prove even more challenging for the remaining branded antiplatelet drugs.
The decision by the German pharmaceutical arbitration committee to include countries such as Greece in a final pricing mechanism will cut German prices and may have a Europe-wide effect.